Funding discovery and innovation

The Center for Diabetes and Metabolic Diseases (CDMD) at the Indiana University School of Medicine is an NIH-funded diabetes research center that includes more than seventy investigators engaged in basic and translational research in diabetes and related metabolic disorders, and their complications. The CDMD also houses four Research Cores that serve as a vital resource for innovative and translational research.

The Sciences Clinical and Translation Institute (CTSI) is a statewide collaboration of Indiana University, Purdue University, and the University of Notre Dame, as well as public and private partnerships, which facilitates the translation of scientific discoveries in the lab into clinical trials and new patient treatments in Indiana and beyond.

Cook Medical is the world’s largest private medical device manufacturer, specializing in vascular complications and regenerative medicine.

Corteva Agriscience (formerly Dow AgroSciences) focuses its research and development on innovative chemical and biotechnology solutions to meet the food, feed and fiber needs of the world. The company delivers a broad range of technologies in plant genetics and food production, including agricultural chemicals, biotechnology and germplasm.

Eli Lilly and Company is a global leader in the development of insulin and diabetes medicines and was the first company to make insulin commercially available. The company continues its leadership position by being the first to bring a wide variety of diabetes advancements to market.  

The Interdisciplinary Center for Network Science and Applications at the University of Notre Dame is an interdisciplinary research center organized around network and data science problems in social, biological, physical, environmental, financial, business, and defense systems.

Indiana University Health is a statewide system with more than 20 partner hospitals and health centers throughout Indiana.  As an academic medical center, IU Health is associated with Indiana University School of Medicine, one of the nation's largest medical schools and the site of thousands of research projects and clinical trials.

Roche Diagnostics, through a complete test portfolio specific to metabolism, as well as through self-testing solutions for patients, is the market leader in diagnosis and monitoring of diabetes and metabolic disorders.

Regenstrief Institute: Founded in 1969 in Indianapolis, Indiana, the Regenstrief Institute is a local, national and global leader dedicated to a world where better information empowers people to end disease and realize true health. The Regenstrief Institute and its researchers are responsible for a growing number of major health care innovations and studies. Examples range from the development of global health information technology standards that enable the use and interoperability of electronic health records to improving patient-physician communications, to the creation of models of care that inform practice and improve the lives of patients around the globe. The Regenstrief Institute is one of the first organizations in the nation to create and use electronic medical records.

Research is embedded within the academic programs and culture of Marian University as an opportunity for students to engage with faculty mentors in inquiry-based learning. Our collaboration with the Indiana Biosciences Research Institute is especially beneficial for expanding the research environment and capabilities for teams engaged in biomedical research from the College of Osteopathic Medicine and the College of Arts & Sciences. In particular, the MU Satellite Lab at the IBRI will provide access to cutting-edge instrumentation and animal facilities that will enrich the student experience, while also advancing faculty research programs and increasing competitiveness for extramural funding.

Adipo Therapeutics is a biotech start-up founded by Purdue Professor Meng Deng, PhD. Adipo is developing a breakthrough technology platform of locally delivered Noth-inhibiting nanoparticles to transform fat, converting energy storing white fat to energy burning brown fat.  This new technology has the potential to revolutionize treatment for type 2 diabetes, obesity and cardiovascular disease.

FAST BioMedical is a privately held company based in Indianapolis developing late clinical-stage medical technology. The company’s globally patented technology is the first to directly measure blood volume and kidney function in a clinically actionable way, which has the potential for significant impact on the treatment of patients with heart failure, cardio-renal syndrome, major surgery, sepsis and acute kidney injury. FAST BioMedical has completed four Human Trials in Germany and the United States. These products are investigational and not yet approved for human use.

GenePace Laboratories is an innovative clinical laboratory focused on molecular diagnostics, operating within the IBRI facilities in the 16 Tech Innovation District near Downtown Indianapolis.

Helix BioStructures is a contract research organization providing integrated early drug discovery services to the biopharmaceutical industry. Helix’s core services encompass drug design and development, chemical and structural analysis, protein production and purification, and computational modeling and design.

Xylogenics, Inc. is a synthetic biology company that creates valuable, non-consumed, yeast to enable fermentation based production of natural products. Xylogenics is redefining fermentation, starting with a flagship product for the fuel ethanol market. Xylogenics intends to be at the forefront of the bio-chemical movement creating sustainable solutions for a variety of rapidly expanding markets.